Human pancreatic LNs contain a sympathetic neuro-immune link that could be targeted for T1D treatment. The proximal CHA's nerve plexus appears the most promising neuromodulation site owing to its surgical accessibility, sympathetic predominance, and suitability for safe device implantation.
Bruinenberg et al. (Sun,) studied this question.